press release

August 2, 2018

– Received Positive CHMP Opinion for ONPATTRO™ in Europe for the Treatment of hATTR Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy and On Track for August 11 PDUFA Date in U.S. – – Achieved Robust Enrollment in ENVISION Phase 3 Study of Givosiran and On Track to Report Topline Results from Interim Analysis for Potential Accelerated Approval ...

press release

July 23, 2018

− Patisiran Treated Patients Showed Improvements in Overall Health Status Compared to Placebo − − Indirect Analysis Shows Patisiran’s Impact on Measures of Neuropathy and Quality of Life in APOLLO Study Relative to those Measured in Randomized Study of Tafamidis − − Improvements in Neuropathy Impairment with Patisiran Treatment Associated with Ambulatory Status − CAMBRIDGE, Mass. (BUSINESS WIRE) Jul. 23, 2018 ...

press release

July 4, 2018

− In Patients with Hereditary ATTR Amyloidosis, Patisiran Treatment Improved Polyneuropathy and Quality of Life Relative to Placebo − − Majority of Patients Receiving Patisiran Experienced Improvement in Polyneuropathy and Quality of Life Relative to Baseline − CAMBRIDGE, Mass. (BUSINESS WIRE) Jul. 4, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the pivotal study results ...

press release

June 20, 2018

− Company Appoints Senior Vice President, Head of Asia and Senior Vice President, Head of Medical Affairs – CAMBRIDGE, Mass. (BUSINESS WIRE) Jun. 20, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointments of two accomplished biotech executives, Masako Nakamura as Senior Vice President, Head of Asia, and Jing L. Marantz, M.D., Ph.D., as Senior ...

press release

June 15, 2018

CAMBRIDGE, Mass. (BUSINESS WIRE) Jun. 15, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at the 4thCongress of the European Academy of Neurology (EAN), being held June 16 19, 2018 ...

press release

May 15, 2018

CAMBRIDGE, Mass. (BUSINESS WIRE) May 15, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylam’s Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of Health Care Service Corporation (HCSC), the largest customer owned health insurer in the United ...

press release

May 3, 2018

– Presented Positive New Clinical Results from APOLLO Phase 3 Study of Patisiran, and Phase 1 and Phase 1/2 Open Label Extension (OLE) Studies of Givosiran – – Advanced Two Additional RNAi Therapeutics in Phase 3 Development: Inclisiran in ORION 9, 10, and 11 Studies, and Fitusiran in the ATLAS Program – – Company Provides Positive New Development Updates on Phase ...

press release

April 24, 2018

− In New Post Hoc Analysis, Patisiran Reduced the Composite Rate of All Cause Hospitalization and Mortality by Approximately 50 Percent, Relative to Placebo − − In Addition, Patisiran Demonstrated Improvement in Multiple Quality of Life Measures, Compared to Placebo − − Analysis of Alnylam Act™ Genetic Testing Program Shows Identification of Pathogenic Transthyretin (TTR) Mutations in Approximately 7.5 Percent of ...

press release

March 28, 2018

− Patisiran Demonstrated Improvement of Cardiomyopathy in Prospectively Defined Subgroup of Patients with Cardiac Amyloid Involvement, Relative to Placebo − − Long term Treatment with Patisiran in Global Open Label Extension (OLE) Study Demonstrates Maintenance of Efficacy and Consistent Safety − − Degree of Patisiran Mediated TTR Knockdown Found to Correlate with Neurologic Improvement – − New Phase 1 Data on ...

press release

March 21, 2018

Collaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseases /* Style Definitions */ span.prnews_span { font size:8pt; font family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font size:8pt; font family:"Arial"; ...